1 / 9

The promise of personalised medicine What happens when we’re all special?

Explore the challenges and opportunities of personalised medicine in meeting individual healthcare needs within a universal healthcare system. Discuss the changing value proposition of medicines and the need for new ways to assess and reward their value based on both individual and societal benefits. Highlight the importance of access for Indigenous and paediatric patients and the potential for new initiatives to drive wider systemic change.

jasonford
Download Presentation

The promise of personalised medicine What happens when we’re all special?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The promise of personalised medicine What happens when we’re all special? Deborah Waterhouse, General Manager GlaxoSmithKline Australia and New Zealand

  2. Issues summary • Multiple challenges meeting individual needs in universal system • HTA designed to distribute limited resources and produce best value for society • The value proposition for medicines is changing as more personalised medicines become available • How do we balance individual and societal needs? • Can we find new ways to assess and reward a medicine’s value based on both individual and societal benefits?

  3. Particular needs Distinct features

  4. The personalised medicine era

  5. Where is the tipping point?

  6. Data uncertainty Trial design Outcome measures Quality Adjusted Life Years Individual contributions

  7. Wider systemic change New initiatives

  8. A new dialogue

  9. Key points • Access for Indigenous and paediatric patients is a priority • New initiatives to improve outcomes for these groups are worth trialling • These can act as pilots for wider systemic change as more personalised medicines become available • Australia is a world leader in HTA and ideally placed to deliver innovation in HTA • This will require a new dialogue between industry, government and the community.

More Related